Literature DB >> 24603884

High prevalence and no latitude gradient of multiple sclerosis in Norway.

P Berg-Hansen1, S M Moen2, H F Harbo2, E G Celius2.   

Abstract

The prevalence of multiple sclerosis (MS) is increasing, and the presence of a latitude gradient for MS risk is still discussed. We present the first nationwide prevalence estimates for Norway, spanning the latitudes from 58-71 degrees North, in order to identify a possible latitude gradient. Information from the Oslo MS Registry and the Norwegian MS Registry and Biobank was combined with data from the Norwegian Patient Registry, the Norwegian Prescription Database and Statistics Norway. We estimated a crude prevalence of 203/100,000 on 1 January 2012. The prevalence in the Northern and Southern regions were not significantly different. MS prevalence in Norway is among the highest reported worldwide. We found no evidence of a latitude gradient.
© The Author(s) 2014.

Entities:  

Keywords:  Epidemiology; Norway; latitude; latitude gradient; multiple sclerosis; prevalence

Mesh:

Year:  2014        PMID: 24603884     DOI: 10.1177/1352458514525871

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  15 in total

1.  Sex ratio in multiple sclerosis mortality over 65 years; an age-period-cohort analysis in Norway.

Authors:  Ola Nakken; Jonas Christoffer Lindstrøm; Trygve Holmøy
Journal:  J Neurol       Date:  2018-03-21       Impact factor: 4.849

Review 2.  Environmental control of autoimmune inflammation in the central nervous system.

Authors:  Veit Rothhammer; Francisco J Quintana
Journal:  Curr Opin Immunol       Date:  2016-10-04       Impact factor: 7.486

3.  Long-term effects of latitude, ambient temperature, and ultraviolet radiation on the incidence of multiple sclerosis in two cohorts of US women.

Authors:  Thao Lam; Trang VoPham; Kassandra L Munger; Francine Laden; Jaime E Hart
Journal:  Environ Epidemiol       Date:  2020-07-06

Review 4.  Time trends in the incidence and prevalence of multiple sclerosis in Norway during eight decades.

Authors:  N Grytten; Ø Torkildsen; K-M Myhr
Journal:  Acta Neurol Scand       Date:  2015       Impact factor: 3.209

5.  Allelic imbalance of multiple sclerosis susceptibility genes IKZF3 and IQGAP1 in human peripheral blood.

Authors:  Pankaj K Keshari; Hanne F Harbo; Kjell-Morten Myhr; Jan H Aarseth; Steffan D Bos; Tone Berge
Journal:  BMC Genet       Date:  2016-04-14       Impact factor: 2.797

6.  A 60-year follow-up of the incidence and prevalence of multiple sclerosis in Hordaland County, Western Norway.

Authors:  N Grytten; J H Aarseth; H M B Lunde; K M Myhr
Journal:  J Neurol Neurosurg Psychiatry       Date:  2015-02-24       Impact factor: 10.154

7.  Comments on the review article 'Time trends in the incidence and prevalence of multiple sclerosis in Norway during eight decades'.

Authors:  P Berg-Hansen; S M Moen; H F Harbo; E G Celius
Journal:  Acta Neurol Scand       Date:  2015-10-01       Impact factor: 3.209

8.  Prevalence of multiple sclerosis in Cuenca, Ecuador.

Authors:  Edgar Patricio Correa-Díaz; María Angélica Ortiz; Ana María Toral; Fernando Guillen; Enrique Terán; Daniel Ontaneda; María García-Castillo; Carolina Jácome-Sánchez; Germaine Torres-Herrán; Andrés Ortega-Heredia; María Eugenia Buestán; Juan Murillo-Calle; Praneeta Raza; Guillermo Baño
Journal:  Mult Scler J Exp Transl Clin       Date:  2019-10-30

9.  Antiepileptic and Antidepressive Polypharmacy in Patients with Multiple Sclerosis.

Authors:  Georg Anton Giæver Beiske; Trygve Holmøy; Antonie Giæver Beiske; Svein I Johannessen; Cecilie Johannessen Landmark
Journal:  Mult Scler Int       Date:  2015-06-29

10.  The multiple sclerosis susceptibility genes TAGAP and IL2RA are regulated by vitamin D in CD4+ T cells.

Authors:  T Berge; I S Leikfoss; I S Brorson; S D Bos; C M Page; M W Gustavsen; A Bjølgerud; T Holmøy; E G Celius; J Damoiseaux; J Smolders; H F Harbo; A Spurkland
Journal:  Genes Immun       Date:  2016-01-14       Impact factor: 2.676

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.